Edwards Lifesciences EW Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net Sales by Business | |||||
| Europe | $1.52B+14.8% | $1.32B+8.1% | $1.22B+17.5% | $1.04B-5.4% | |
| Japan | $354.7M+4.4% | $339.8M-9.6% | $376M— | —— | |
| Rest of World | $652.3M+14.0% | $572M-0.2% | $573M+27.6% | $449.1M-15.8% | |
| United States | $3.54B+10.5% | $3.21B+3.7% | $3.09B+17.6% | $2.63B-11.3% | |
| Total other segment items by Business | |||||
| Europe | $66.2M+344% | $14.9M+472% | -$4M+88.5% | -$34.9M— | |
| Japan | -$10M-47.1% | -$6.8M-132% | $21.3M+137% | -$58.1M— | |
| Rest of World | -$26.4M-151% | -$10.5M-2,000% | -$500K+73.7% | -$1.9M— | |
| United States | $2.5M+4.2% | $2.4M+14.3% | $2.1M-56.3% | $4.8M— | |
| Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest by Business | |||||
| Europe | $796.2M+9.8% | $725.1M+8.3% | $669.7M+10.8% | $604.3M+6.2% | |
| Japan | $233.8M+9.6% | $213.4M-5.1% | $224.8M-24.7% | $298.7M-14.2% | |
| Rest of World | $298.5M+22.8% | $243M-1.9% | $247.6M+39.1% | $178M-3.9% | |
| United States | $2.35B+8.6% | $2.16B+3.9% | $2.08B+11.5% | $1.86B-9.1% | |
| Selling, general, and administrative expenses by Business | |||||
| Europe | $315M+11.5% | $282.6M+8.4% | $260.6M+11.8% | $233M— | |
| Japan | $78.5M-7.8% | $85.1M+21.4% | $70.1M-9.4% | $77.4M— | |
| Rest of World | $209.6M+15.5% | $181.4M+9.0% | $166.4M+16.7% | $142.6M— | |
| United States | $575.3M+15.5% | $498M+15.1% | $432.8M+27.0% | $340.7M— | |
| Cost of Sales by Business | |||||
| Europe | $340.1M+13.7% | $299.1M+11.4% | $268.5M+12.9% | $237.9M— | |
| Japan | $52.4M+8.9% | $48.1M+3.2% | $46.6M+12.3% | $41.5M— | |
| Rest of World | $170.6M+7.9% | $158.1M+16.1% | $136.2M+15.2% | $118.2M— | |
| United States | $620.3M+13.5% | $546.6M+8.2% | $505.2M+20.6% | $418.9M— | |
| Currency translation adjustment by Business | |||||
| Europe | $7M+333% | -$3M-258% | $1.9M+153% | -$3.6M+32.1% | |
| Rest of World | $0— | $0— | $0— | $0— | |
| United States | $0— | $0— | $0— | $0— | |
| Adjustments to goodwill from acquisition by Business | |||||
| Europe | $0— | —— | —— | —— | |
| Rest of World | $0— | —— | —— | —— | |
| United States | -$15.1M— | —— | —— | —— | |
| Net Sales by Product | |||||
| Transcatheter Aortic Valve Replacement | $4.49B+9.3% | $4.11B+5.8% | $3.88B+10.3% | $3.52B+2.8% | |
| Transcatheter Mitral and Tricuspid Therapies | $550.6M+56.4% | $352.1M+78.2% | $197.6M+70.2% | $116.1M+35.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Edwards Lifesciences break its business down?
- Edwards Lifesciences (EW) reports net sales by business across 4 parts — Europe, Japan, Rest of World and United States. Each is extracted from the segment footnotes and tracked over time.
- Where does Edwards Lifesciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Edwards Lifesciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
